These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8576932)

  • 1. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension.
    Haikala H; Levijoki J; Lindén IB
    J Mol Cell Cardiol; 1995 Oct; 27(10):2155-65. PubMed ID: 8576932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation.
    Haikala H; Nissinen E; Etemadzadeh E; Levijoki J; Lindén IB
    J Cardiovasc Pharmacol; 1995 May; 25(5):794-801. PubMed ID: 7630157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of action of calcium-sensitizing drugs.
    Haikala H; Linden IB
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S10-9. PubMed ID: 8907127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics.
    Hasenfuss G; Pieske B; Kretschmann B; Holubarsch C; Alpert NR; Just H
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S45-51. PubMed ID: 8907130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition.
    Kaheinen P; Pollesello P; Hertelendi Z; Borbély A; Szilágyi S; Nissinen E; Haikala H; Papp Z
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):74-8. PubMed ID: 16433895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers.
    Lues I; Beier N; Jonas R; Klockow M; Haeusler G
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):883-92. PubMed ID: 7687712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone.
    Szilágyi S; Pollesello P; Levijoki J; Haikala H; Bak I; Tósaki A; Borbély A; Edes I; Papp Z
    J Cardiovasc Pharmacol; 2005 Sep; 46(3):369-76. PubMed ID: 16116344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit.
    Sato S; Talukder MA; Sugawara H; Sawada H; Endoh M
    J Mol Cell Cardiol; 1998 Jun; 30(6):1115-28. PubMed ID: 9689586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan.
    Haikala H; Kaheinen P; Levijoki J; Lindén IB
    Cardiovasc Res; 1997 Jun; 34(3):536-46. PubMed ID: 9231037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium.
    Uhlmann R; Schwinger RH; Lues I; Erdmann E
    Basic Res Cardiol; 1995; 90(5):365-71. PubMed ID: 8585857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium.
    Hasenfuss G; Pieske B; Castell M; Kretschmann B; Maier LS; Just H
    Circulation; 1998 Nov; 98(20):2141-7. PubMed ID: 9815868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart.
    Edes I; Kiss E; Kitada Y; Powers FM; Papp JG; Kranias EG; Solaro RJ
    Circ Res; 1995 Jul; 77(1):107-13. PubMed ID: 7788868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel cardiotonic agent EMD 53 998 is a potent "calcium sensitizer".
    Beier N; Harting J; Jonas R; Klockow M; Lues I; Haeusler G
    J Cardiovasc Pharmacol; 1991 Jul; 18(1):17-27. PubMed ID: 1719287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of Ca2+ sensitizers--update 2001.
    Endoh M
    Cardiovasc Drugs Ther; 2001 Sep; 15(5):397-403. PubMed ID: 11855658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan, a new inotropic and vasodilator agent.
    Toller WG; Stranz C
    Anesthesiology; 2006 Mar; 104(3):556-69. PubMed ID: 16508404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization.
    Bowman P; Haikala H; Paul RJ
    J Pharmacol Exp Ther; 1999 Jan; 288(1):316-25. PubMed ID: 9862786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac Ca2+ signaling and Ca2+ sensitizers.
    Endoh M
    Circ J; 2008 Dec; 72(12):1915-25. PubMed ID: 18981594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac electrophysiological effects of levosimendan, a new calcium sensitizer.
    Virág L; Hála O; Marton A; Varró A; Papp JG
    Gen Pharmacol; 1996 Apr; 27(3):551-6. PubMed ID: 8723543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.
    Orstavik O; Ata SH; Riise J; Dahl CP; Andersen GØ; Levy FO; Skomedal T; Osnes JB; Qvigstad E
    Br J Pharmacol; 2014 Dec; 171(23):5169-81. PubMed ID: 24547784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan in regional myocardial ischemia.
    Pieske B
    Cardiovasc Drugs Ther; 2002 Sep; 16(5):379-81. PubMed ID: 12656119
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.